Oncosil Medical Ltd (OSL) - Net Assets

Latest as of December 2025: AU$3.84 Million AUD ≈ $2.71 Million USD

Based on the latest financial reports, Oncosil Medical Ltd (OSL) has net assets worth AU$3.84 Million AUD (≈ $2.71 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$7.13 Million ≈ $5.05 Million USD) and total liabilities (AU$3.29 Million ≈ $2.33 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Oncosil Medical Ltd to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$3.84 Million
% of Total Assets 53.8%
Annual Growth Rate 6.39%
5-Year Change -73.47%
10-Year Change -79.05%
Growth Volatility 122.21

Oncosil Medical Ltd - Net Assets Trend (2005–2025)

This chart illustrates how Oncosil Medical Ltd's net assets have evolved over time, based on quarterly financial data. Also explore OSL total assets for the complete picture of this company's asset base.

Annual Net Assets for Oncosil Medical Ltd (2005–2025)

The table below shows the annual net assets of Oncosil Medical Ltd from 2005 to 2025. For live valuation and market cap data, see Oncosil Medical Ltd market cap and net worth.

Year Net Assets Change
2025-06-30 AU$3.10 Million
≈ $2.20 Million		 -34.48%
2024-06-30 AU$4.74 Million
≈ $3.35 Million		 -52.06%
2023-06-30 AU$9.88 Million
≈ $6.99 Million		 -11.49%
2022-06-30 AU$11.16 Million
≈ $7.90 Million		 -4.56%
2021-06-30 AU$11.70 Million
≈ $8.28 Million		 -46.59%
2020-06-30 AU$21.90 Million
≈ $15.50 Million		 +105.16%
2019-06-30 AU$10.68 Million
≈ $7.55 Million		 -41.20%
2018-06-30 AU$18.15 Million
≈ $12.85 Million		 +79.13%
2017-06-30 AU$10.13 Million
≈ $7.17 Million		 -31.57%
2016-06-30 AU$14.81 Million
≈ $10.48 Million		 +112.75%
2015-06-30 AU$6.96 Million
≈ $4.93 Million		 -26.84%
2014-06-30 AU$9.52 Million
≈ $6.73 Million		 +57.26%
2013-06-30 AU$6.05 Million
≈ $4.28 Million		 +143.70%
2012-06-30 AU$2.48 Million
≈ $1.76 Million		 -14.77%
2011-06-30 AU$2.91 Million
≈ $2.06 Million		 +13.01%
2010-06-30 AU$2.58 Million
≈ $1.82 Million		 -39.80%
2009-06-30 AU$4.28 Million
≈ $3.03 Million		 +4.77%
2008-06-30 AU$4.09 Million
≈ $2.89 Million		 -12.66%
2007-06-30 AU$4.68 Million
≈ $3.31 Million		 -14.25%
2006-06-30 AU$5.46 Million
≈ $3.86 Million		 +506.67%
2005-06-30 AU$899.56K
≈ $636.50K		 --

Equity Component Analysis

This analysis shows how different components contribute to Oncosil Medical Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 10743135100.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Common Stock AU$96.43 Million 3106.96%
Other Comprehensive Income AU$14.14 Million 455.49%
Total Equity AU$3.10 Million 100.00%

Oncosil Medical Ltd Competitors by Market Cap

The table below lists competitors of Oncosil Medical Ltd ranked by their market capitalization.

Company Market Cap
PEREGRINE GOLD LTD
F:9VA
 $8.61 Million
Addex Therapeutics Ltd
NASDAQ:ADXN
 $8.61 Million
GENFLOW BIOSCIENCES PLC
F:WQ5
 $8.61 Million
Gaming Factory S.A.
WAR:GIF
 $8.61 Million
Sonnet Biotherapeutics Holdings Inc
NASDAQ:SONN
 $8.60 Million
TIMES CHINA HLDGS HD -10
F:T2H
 $8.60 Million
Envirotech Vehicles Inc
NASDAQ:EVTV
 $8.60 Million
Korporacja Gospodarcza efekt S.A
WAR:EFK
 $8.59 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Oncosil Medical Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 4,736,409 to 3,103,521, a change of -1,632,888 (-34.5%).
  • Net loss of 15,099,844 reduced equity.
  • Share repurchases of 12,780,620 reduced equity.
  • New share issuances of 12,780,621 increased equity.
  • Other comprehensive income increased equity by 6,712,563.
  • Other factors increased equity by 6,754,392.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$-15.10 Million -486.54%
Share Repurchases AU$12.78 Million -411.81%
Share Issuances AU$12.78 Million +411.81%
Other Comprehensive Income AU$6.71 Million +216.29%
Other Changes AU$6.75 Million +217.64%
Total Change AU$- -34.48%

Book Value vs Market Value Analysis

This analysis compares Oncosil Medical Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.81x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 12.95x to 1.81x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2005-06-30 AU$0.04 AU$0.52 x
2006-06-30 AU$0.11 AU$0.52 x
2007-06-30 AU$0.08 AU$0.52 x
2008-06-30 AU$0.05 AU$0.52 x
2009-06-30 AU$0.05 AU$0.52 x
2010-06-30 AU$0.03 AU$0.52 x
2011-06-30 AU$0.03 AU$0.52 x
2012-06-30 AU$0.02 AU$0.52 x
2013-06-30 AU$0.04 AU$0.52 x
2014-06-30 AU$0.03 AU$0.52 x
2015-06-30 AU$0.02 AU$0.52 x
2016-06-30 AU$0.03 AU$0.52 x
2017-06-30 AU$0.02 AU$0.52 x
2018-06-30 AU$0.03 AU$0.52 x
2019-06-30 AU$0.01 AU$0.52 x
2020-06-30 AU$0.03 AU$0.52 x
2021-06-30 AU$0.01 AU$0.52 x
2022-06-30 AU$0.01 AU$0.52 x
2023-06-30 AU$0.01 AU$0.52 x
2024-06-30 AU$0.00 AU$0.52 x
2025-06-30 AU$0.28 AU$0.52 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Oncosil Medical Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -486.54%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -1289.71%
  • • Asset Turnover: 0.16x
  • • Equity Multiplier: 2.30x
  • Recent ROE (-486.54%) is below the historical average (-79.39%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2005 -2.94% 0.00% 0.00x 1.05x AU$-116.38K
2006 -2.35% -8.47% 0.18x 1.50x AU$-673.74K
2007 -35.77% -95.22% 0.25x 1.50x AU$-2.14 Million
2008 -67.70% -134.06% 0.33x 1.51x AU$-3.18 Million
2009 -10.28% -19.11% 0.44x 1.22x AU$-868.21K
2010 -66.42% -82.03% 0.71x 1.15x AU$-1.97 Million
2011 -50.05% 0.00% 0.00x 1.04x AU$-1.75 Million
2012 -17.36% -262.80% 0.06x 1.02x AU$-679.28K
2013 -14.53% -998.86% 0.01x 1.03x AU$-1.48 Million
2014 -72.17% -2173.45% 0.03x 1.01x AU$-7.82 Million
2015 -41.36% -104.43% 0.37x 1.06x AU$-3.58 Million
2016 -32.20% -124.29% 0.24x 1.07x AU$-6.25 Million
2017 -69.23% -199.66% 0.30x 1.16x AU$-8.03 Million
2018 -47.04% -192.00% 0.22x 1.10x AU$-10.36 Million
2019 -80.25% -236.27% 0.31x 1.09x AU$-9.63 Million
2020 -19.46% -154.20% 0.11x 1.10x AU$-6.45 Million
2021 -89.21% -4896.98% 0.02x 1.21x AU$-11.60 Million
2022 -96.10% -4627.92% 0.02x 1.17x AU$-11.84 Million
2023 -114.80% -3085.04% 0.03x 1.16x AU$-12.33 Million
2024 -251.54% -2306.09% 0.08x 1.42x AU$-12.39 Million
2025 -486.54% -1289.71% 0.16x 2.30x AU$-15.41 Million

Industry Comparison

This section compares Oncosil Medical Ltd's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $78,590,417
  • Average return on equity (ROE) among peers: -30.76%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Oncosil Medical Ltd (OSL) AU$3.84 Million -2.94% 0.86x $8.61 Million
4DMEDICAL Ltd (4DX) $-11.81 Million 0.00% 0.00x $1.63 Billion
Adherium Ltd (ADR) $-4.76 Million 0.00% 0.00x $7.37 Million
Aroa Biosurgery Ltd (ARX) $15.23 Million 0.00% 0.29x $152.13 Million
Atomo Diagnostics Ltd (AT1) $10.08 Million -67.90% 0.13x $13.76 Million
Avita Medical Inc (AVH) $124.47 Million -31.47% 0.16x $130.53 Million
Anteris Technologies Global Corp (AVR) $22.64 Million -106.07% 0.18x $558.50 Million
Control Bionics Ltd (CBL) $292.62 Million 10.16% 3.11x $16.32 Million
Cardiex Ltd (CDX) $6.61 Million -172.18% 0.87x $13.23 Million
Compumedics Ltd (CMP) $11.48 Million 23.76% 0.87x $39.86 Million
Cochlear Ltd (COH) $319.34 Million 36.08% 0.90x $4.57 Billion

About Oncosil Medical Ltd

AU:OSL Australia Medical Devices
Market Cap
$8.61 Million
AU$12.16 Million AUD
Market Cap Rank
#27244 Global
#1391 in Australia
Share Price
AU$0.52
Change (1 day)
+5.10%
52-Week Range
AU$0.00 - AU$1.99
All Time High
AU$1.99
Categories
Companies in Australia Medical Devices
About

OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company's lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorp… Read more